Anna K. Jönsson

2.5k total citations
65 papers, 1.8k citations indexed

About

Anna K. Jönsson is a scholar working on Toxicology, Pediatrics, Perinatology and Child Health and Geriatrics and Gerontology. According to data from OpenAlex, Anna K. Jönsson has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Toxicology, 15 papers in Pediatrics, Perinatology and Child Health and 14 papers in Geriatrics and Gerontology. Recurrent topics in Anna K. Jönsson's work include Pharmacovigilance and Adverse Drug Reactions (15 papers), Forensic Toxicology and Drug Analysis (15 papers) and Pharmaceutical Practices and Patient Outcomes (14 papers). Anna K. Jönsson is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (15 papers), Forensic Toxicology and Drug Analysis (15 papers) and Pharmaceutical Practices and Patient Outcomes (14 papers). Anna K. Jönsson collaborates with scholars based in Sweden, Norway and Denmark. Anna K. Jönsson's co-authors include Staffan Hägg, Olav Spigset, Johan Ahlner, Henrik Druid, Karolina Andersson Sundell, Hanna Gyllensten, Katja M. Hakkarainen, Max Petzold, Per Holmgren and Anders Carlsten and has published in prestigious journals such as The Journal of Chemical Physics, PLoS ONE and Neuroscience.

In The Last Decade

Anna K. Jönsson

64 papers receiving 1.8k citations

Peers

Countries citing papers authored by Anna K. Jönsson

Since Specialization

Citations

This map shows the geographic impact of Anna K. Jönsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna K. Jönsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna K. Jönsson more than expected).

Fields of papers citing papers by Anna K. Jönsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna K. Jönsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna K. Jönsson. The network helps show where Anna K. Jönsson may publish in the future.

Co-authorship network of co-authors of Anna K. Jönsson

This figure shows the co-authorship network connecting the top 25 collaborators of Anna K. Jönsson. A scholar is included among the top collaborators of Anna K. Jönsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna K. Jönsson. Anna K. Jönsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fatal Intoxications with Zopiclone—A Cause for Concern? 2024 ·Drug Safety ·(unknown), (unknown), (unknown), Anna K. Jönsson, Fredrik C. Kugelberg	3
2	Loperamide positive deaths in Sweden 2012–2022 and Finland 2017–2022: Fatal loperamide intoxication exclusively for Sweden 2024 ·Forensic Science International ·(unknown), Pirkko Kriikku, Anna K. Jönsson	0
3	Characteristics of post-mortem beta-hydroxybutyrate-positivet cases – A retrospective study on age, sex and BMI in 1407 forensic autopsies 2021 ·Forensic Science International ·(unknown), Ingemar Thiblin, Anna K. Jönsson, Henrik Gréen	3
4	An imidazole based H-Phe-Phe-NH2 peptidomimetic with anti-allodynic effect in spared nerve injury mice 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Anna Leśniak, Christian Sköld, Maria Karlgren, Fabienne Z. Gaugaz, Richard Svensson, Shanti Diwakarla, Anna K. Jönsson, Rebecca Fransson, Fred Nyberg, Mathias Hallberg, Anja Sandström	3
5	Comparing Methods for Estimating Direct Costs of Adverse Drug Events 2017 ·Value in Health ·Hanna Gyllensten, Anna K. Jönsson, Katja M. Hakkarainen, Staffan Svensson, Staffan Hägg, Clas Rehnberg	6
6	Adherence to antidepressants among women and men described with trajectory models: a Swedish longitudinal study 2016 ·European Journal of Clinical Pharmacology ·Ann‐Charlotte Mårdby, Linus Schiöler, Karolina Andersson Sundell, (unknown), Eva Lesén, Anna K. Jönsson	12
7	Refill Adherence in Relation to Substitution and the Use of Multiple Medications: A Nationwide Population Based Study on New ACE-Inhibitor Users 2016 ·PLoS ONE ·(unknown), Anna K. Jönsson, Eva Lesén, Ann‐Charlotte Mårdby, Karolina Andersson Sundell	1
8	Small constrained SP1–7 analogs bind to a unique site and promote anti-allodynic effects following systemic injection in mice 2015 ·Neuroscience ·Anna K. Jönsson, Rebecca Fransson, (unknown), (unknown), (unknown), Hiroyuki Watanabe, Gunnar Nordvall, Mathias Hallberg, Anja Sandström, Fred Nyberg	8
9	The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting 2015 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg, Anna K. Jönsson	15
10	Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults 2014 ·PLoS ONE ·Hanna Gyllensten, Katja M. Hakkarainen, Staffan Hägg, Anders Carlsten, Max Petzold, Clas Rehnberg, Anna K. Jönsson	49
11	Sedative and hypnotic drugs—Fatal and non-fatal reference blood concentrations 2014 ·Forensic Science International ·Anna K. Jönsson, (unknown), (unknown), Johan Ahlner, Anders Eriksson, Margareta Reis, Henrik Druid	32
12	Is the level of patient co-payment for medicines associated with refill adherence in Sweden? 2013 ·European Journal of Public Health ·Eva Lesén, Karolina Andersson Sundell, A. Carlsten, Ann‐Charlotte Mårdby, Anna K. Jönsson	18
13	How are the Costs of Drug-Related Morbidity Measured? 2012 ·Drug Safety ·Hanna Gyllensten, Anna K. Jönsson, Clas Rehnberg, Anders Carlsten	16
14	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists’ 2012 ·International Journal of Clinical Pharmacy ·Hanna Gyllensten, Katja M. Hakkarainen, Anna K. Jönsson, Karolina Andersson Sundell, Staffan Hägg, Clas Rehnberg, Anders Carlsten	10
15	Caffeine fatalities – Do sales restrictions prevent intentional intoxications? 2010 ·Clinical Toxicology ·Gunilla Thelander, Anna K. Jönsson, Mark Personne, (unknown), (unknown), Johan Ahlner	52
16	Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden 2009 ·Pharmacoepidemiology and Drug Safety ·(unknown), Anna K. Jönsson, Barbro Gerdén, Staffan Hägg	57
17	Risk of venous thromboembolism due to antipsychotic drug therapy 2009 ·Expert Opinion on Drug Safety ·Staffan Hägg, Anna K. Jönsson, Olav Spigset	62
18	Incidence of fatal adverse drug reactions: a population based study 2007 ·British Journal of Clinical Pharmacology ·(unknown), Anna K. Jönsson, Olav Spigset, Henrik Druid, Staffan Hägg	238
19	The IGF-system is not affected by a twofold change in protein intake in patients with type 1 diabetes 2005 ·Growth Hormone & IGF Research ·Christina A. Hedman, Jan Frystyk, (unknown), Anna K. Jönsson, Allan Flyvbjerg, Torbjörn Lindström, Hans J. Arnqvist	5
20	Motor neuron disease in transgenic mice and a patient carrying the G127insTGGG CuZn-superoxide dismutase mutation 1999 ·The Society for Neuroscience Abstracts ·Stefan L. Marklund, Peter Nilsson, Anna K. Jönsson, Thomas Brännström, (unknown), P. M. Andersen, Lars Forsgren, Ole Gredal	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact